Limitations in Treatment of Metastatic Renal Cell Carcinoma

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.